GeNOsys
Incorporated
Generated Nitric Oxide Systems
Shareholder letter
September 8, 2008
Dear GeNOsys Shareholder,
I would like to take this opportunity to update you on the Company's progress since our previous shareholder letter of 18, March, 2008. Since that point, we have made tremendous strides toward completing our mission of developing on-site generation and delivery of medical grade Nitric Oxide gas.
The Company is focused on its product line of portable and inexpensive Nitric Oxide (NO) gas generators for the control and treatment of tuberculosis and other human disease.
The following letter will help you understand the Company's timeline (including where we are as of today and the regulatory process), exactlywhat Nitric Oxide does and why it is important inthe fight of Tuberculosis,how ournew patented technologycompares to the currentexpensive old technology,and themarket potentialfor Nitric Oxide (NO) gas generators.
I hope, from this letter, you better understand how important it is to provide the medical community with a better and more affordable way to deliver medical grade Nitric Oxide gas. The world needs it and we expect our shareholders to benefit from this important development.
Best regards,
Clark Mower
GeNOsys Chairman of the Board of Directors
This shareholder letter may contain forward-looking statements including the Company's beliefs about its business prospects and future results of operations. These statements involve risks and uncertainties. Among the important additional factors that could cause actual results to differ materially from those forward-looking statements are risks associates with the overall economic environment, changes in anticipated earnings of the company and other factors detailed in the company's filings with the SEC. In addition, the factors underlying Company forecasts are dynamic and subject to change and therefore those forecasts speck only as of the date they are given. The Company does not undertake to update them; however, it may choose from time to time to update them and if it should do so, it will disseminate the updates to the investing public.
For further information:
GeNOsys Inc.
Investor Relations:
280 West Riverpark Drive
Michael Dancy
Provo, Utah 84604
(801) 746-3570
(801) 623-4751
medancy@allwest.net
clark@genosysusa.com
kmerrell@genosysusa.com
http://www.genosysusa.com
